Rapport Therapeutics’ (NASDAQ:RAPP – Get Free Report) lock-up period will end on Wednesday, December 4th. Rapport Therapeutics had issued 8,000,000 shares in its public offering on June 7th. The total size of the offering was $136,000,000 based on an initial share price of $17.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.
Rapport Therapeutics Price Performance
Shares of RAPP stock opened at $22.39 on Friday. The business’s 50-day moving average price is $23.09. Rapport Therapeutics has a 12-month low of $16.55 and a 12-month high of $29.74.
Institutional Investors Weigh In On Rapport Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Barclays PLC raised its stake in shares of Rapport Therapeutics by 36.8% during the third quarter. Barclays PLC now owns 12,863 shares of the company’s stock valued at $264,000 after acquiring an additional 3,463 shares during the last quarter. Geode Capital Management LLC bought a new stake in Rapport Therapeutics in the third quarter worth $4,133,000. State Street Corp bought a new position in shares of Rapport Therapeutics during the third quarter valued at $1,189,000. Maven Securities LTD bought a new position in shares of Rapport Therapeutics during the third quarter valued at $613,000. Finally, Eventide Asset Management LLC raised its position in shares of Rapport Therapeutics by 120.8% in the 3rd quarter. Eventide Asset Management LLC now owns 110,401 shares of the company’s stock worth $2,261,000 after purchasing an additional 60,401 shares during the last quarter.
About Rapport Therapeutics
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Further Reading
- Five stocks we like better than Rapport Therapeutics
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- How to Calculate Inflation Rate
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- Trading Stocks: RSI and Why it’s Useful
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
